
Voyager Therapeutics, Inc.
VYGRHealthcare|Biotechnology|US
$1.86
+0.14 (+8.43%)
Tangible Book / Share
$2.19
Cash / Share
$1.73
Next Earnings Report
Mar 8, 2027
EPS est. -$0.34 · Revenue est. $8.1M
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Dec 1, 2025 (424B3). Possible dilution.
Upcoming Data Readouts (2)
Mar 2027
Est. completion
Apr 2029
Est. completion
P1Alzheimer s Disease
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
NCT07764146n=18
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P1P2
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621Recent Press Releases
Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026
Oct 27, 2026 · GlobeNewsWire
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
Oct 21, 2026 · GlobeNewsWire
Voyager to Present at Upcoming Investor Conferences
Sep 1, 2026 · GlobeNewsWire
SEC Filings (56)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 5, 2026 | 8-K | Material event | DocumentIndex |
| Nov 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 21, 2026 | 8-K | Material event | DocumentIndex |
| Aug 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2026 | 8-K | Material event | DocumentIndex |
| Aug 6, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 31, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Jul 13, 2026 | 8-K | Material event | DocumentIndex |
| Jun 10, 2026 | 8-K | Material event | DocumentIndex |
| Jun 1, 2026 | 8-K | Material event | DocumentIndex |
| May 15, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 15, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 7, 2026 | 8-K | Material event | DocumentIndex |
| May 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 28, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 28, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 28, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 21, 2026 | 8-K | Material event | DocumentIndex |
| Apr 10, 2026 | PRE 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 9, 2026 | 8-K | Material event | DocumentIndex |
| Mar 9, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 18, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 17, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 12, 2026 | 8-K | Material event | DocumentIndex |
| Jan 26, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Jan 8, 2026 | 8-K | Material event | DocumentIndex |
| Dec 1, 2025 | EFFECT | DocumentIndex | |
| Dec 1, 2025 | 424B3 | Offering prospectus | DocumentIndex |
| Nov 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 10, 2025 | S-3 | Shelf registration | DocumentIndex |
| Nov 10, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 10, 2025 | 8-K | Material event | DocumentIndex |
| Sep 2, 2025 | 8-K | Material event | DocumentIndex |
| Aug 14, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Aug 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 6, 2025 | 8-K | Material event | DocumentIndex |
| Jun 9, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Jun 5, 2025 | 8-K | Material event | DocumentIndex |